Cancer caused about 10 million deaths worldwide in 2020. Projections estimate new cases and deaths will rise by 28% to 47% by 2040. This article details the global burden, treatment gaps, and the impact of prevention.
Key Takeaways
- 44% of cancer deaths occur in Asia, according to GLOBOCAN 2020 regional distribution
- Cancer incidence and mortality were estimated to rise by 28% to 47% between 2020 and 2040 for new cases and deaths (respectively), per GLOBOCAN projection work
- Cancer accounted for about 10.0 million deaths in 2020 (all-cause cancer mortality), per Global Burden of Disease comparisons
- In the Global Cancer Observatory, there are country-level, site-specific cancer incidence and mortality estimates for all WHO member states (coverage is comprehensive)
- The Lancet Oncology and other analyses quantify the ‘treatment gap’ in LMICs; for example, radiotherapy shortfalls are estimated in patients per million population
- About 1.0 billion people worldwide lack access to safe, timely and affordable surgical care (relevant to cancer treatment pathways), per Lancet Global Health
- About 5–10% of all cancers are linked to infections (including HBV/HCV, HPV, H. pylori), per WHO/FAO-hosted cancer infection reviews
- In 2020, only around 20% of eligible women globally had access to cervical cancer screening (estimated), per WHO cervical cancer control estimates
- WHO recommends HPV testing and/or HPV vaccination as core elements for cervical cancer control; WHO guidance includes measurable targets for screening approaches
- 35% of cancer burden is attributable to diet, weight, physical activity, and alcohol-related factors, per World Cancer Research Fund assessment
- WHO estimated 2.9 million deaths from tobacco use in 2019 worldwide, supporting the tobacco-attributable cancer burden
- WHO estimates that alcohol causes 741,000 deaths annually worldwide, with a fraction attributable to cancers
- Cancer treatment contributes heavily to out-of-pocket spending; a WHO study reports median household out-of-pocket expenditures for cancer can be catastrophic (reported as thresholds in the study)
- The global radiotherapy equipment market value was projected to reach roughly $7–8 billion by the early 2020s (varies by source and definition), reflecting capital costs for cancer care
- The global medical imaging market was estimated at about $30+ billion (recent years), supporting downstream spending for cancer diagnostics
With 44% of deaths in Asia and rising future cases, prevention, early detection, and better access are urgent worldwide.
Related reading
01 · Category
Global Burden7 stats
01
44% of cancer deaths occur in Asia, according to GLOBOCAN 2020 regional distribution
02
Cancer incidence and mortality were estimated to rise by 28% to 47% between 2020 and 2040 for new cases and deaths (respectively), per GLOBOCAN projection work
03
Cancer accounted for about 10.0 million deaths in 2020 (all-cause cancer mortality), per Global Burden of Disease comparisons
04
In 2020, breast cancer had about 2.3 million new cases worldwide, making it the most commonly diagnosed cancer type
05
In 2020, the leading cancer type by deaths was lung cancer with about 1.8 million deaths worldwide, per GLOBOCAN 2020 factsheet
06
In 2020, colorectal cancer had about 1.9 million new cases worldwide, per GLOBOCAN 2020 cancer factsheet
07
In 2020, liver cancer caused about 830,000 deaths worldwide, per GLOBOCAN 2020 factsheet
Interpretation
Global Burden Interpretation
The global burden of cancer is projected to worsen as incidence and deaths are expected to rise by about 28% to 47% from 2020 to 2040, while Asia already accounts for 44% of cancer deaths and breast, lung, and colorectal cancers together drive millions of new cases each year in 2020.
02 · Category
Policy & Access5 stats
01
In the Global Cancer Observatory, there are country-level, site-specific cancer incidence and mortality estimates for all WHO member states (coverage is comprehensive)
02
The Lancet Oncology and other analyses quantify the ‘treatment gap’ in LMICs; for example, radiotherapy shortfalls are estimated in patients per million population
03
About 1.0 billion people worldwide lack access to safe, timely and affordable surgical care (relevant to cancer treatment pathways), per Lancet Global Health
04
WHO’s Global Initiative for Cervical Cancer Elimination targets eliminating cervical cancer as a public health problem by achieving 90% vaccination coverage, 70% screening coverage, and 90% treatment coverage
05
OECD data show that net mortality-to-incidence differences can be quantified across countries; OECD cancer outcomes reports provide numeric survival and mortality rates by cancer type
Interpretation
Policy & Access Interpretation
Policy and access gaps are central to cancer outcomes because large systems shortages persist, including about 1.0 billion people worldwide lacking safe, timely, and affordable surgical care and substantial treatment gaps in LMICs such as radiotherapy shortfalls, which together underline the urgency of scaling access-focused interventions like WHO’s cervical cancer elimination targets of 90% vaccination.
03 · Category
Screening & Early Detection7 stats
01
About 5–10% of all cancers are linked to infections (including HBV/HCV, HPV, H. pylori), per WHO/FAO-hosted cancer infection reviews
02
In 2020, only around 20% of eligible women globally had access to cervical cancer screening (estimated), per WHO cervical cancer control estimates
03
WHO recommends HPV testing and/or HPV vaccination as core elements for cervical cancer control; WHO guidance includes measurable targets for screening approaches
04
The PPV (positive predictive value) of mammography screening in program settings varies by age and readers; a large systematic review reports typical ranges (to inform early detection performance)
05
Fecal immunochemical test (FIT) screening has sensitivity for colorectal cancer in the range of 60–80% depending on cutoff and population, per meta-analyses
06
Low-dose CT screening for lung cancer reduces lung cancer mortality in high-risk individuals; the NLST showed a 20% reduction in lung cancer deaths with LDCT vs chest X-ray
07
In the NELSON trial, lung cancer screening with low-dose CT reduced lung cancer mortality by 26% compared with no screening
Interpretation
Screening & Early Detection Interpretation
Even though screening and early detection can prevent many cancers, global coverage remains limited, with only about 20% of eligible women receiving cervical cancer screening in 2020, while infection-related cancers account for roughly 5 to 10% of all cases and test performance varies widely across programs and age groups.
04 · Category
Risk & Prevention5 stats
01
35% of cancer burden is attributable to diet, weight, physical activity, and alcohol-related factors, per World Cancer Research Fund assessment
02
WHO estimated 2.9 million deaths from tobacco use in 2019 worldwide, supporting the tobacco-attributable cancer burden
03
WHO estimates that alcohol causes 741,000 deaths annually worldwide, with a fraction attributable to cancers
04
HPV vaccination can prevent a large share of cervical cancer cases; WHO notes vaccination effectiveness against HPV types responsible for most cervical cancers
05
In 2019, 39 million people were living with HIV worldwide, increasing risks of several cancers
Interpretation
Risk & Prevention Interpretation
Together, lifestyle and preventable exposures drive a large share of cancer risk, since 35% of the cancer burden is linked to diet, weight, physical activity, and alcohol, and WHO attributes 2.9 million deaths to tobacco in 2019 while also estimating 741,000 alcohol-related deaths each year, making Risk and Prevention actions such as reducing tobacco and alcohol and using HPV vaccination especially powerful.
05 · Category
Healthcare Costs5 stats
01
Cancer treatment contributes heavily to out-of-pocket spending; a WHO study reports median household out-of-pocket expenditures for cancer can be catastrophic (reported as thresholds in the study)
02
The global radiotherapy equipment market value was projected to reach roughly $7–8 billion by the early 2020s (varies by source and definition), reflecting capital costs for cancer care
03
The global medical imaging market was estimated at about $30+ billion (recent years), supporting downstream spending for cancer diagnostics
04
Oncology clinical trial activity counts are measured by registries; for example, more than 20,000 oncology trials are registered in ClinicalTrials.gov across recent years (observable registry counts)
05
The global cancer therapeutics market is forecast to grow at roughly double-digit CAGR in some industry forecasts, indicating accelerating spend (forecast values reported in vendor research)
Interpretation
Healthcare Costs Interpretation
Healthcare costs for cancer are rising on multiple fronts, with WHO reporting significant median household out-of-pocket spending for cancer and market forecasts showing radiotherapy equipment at around $7 to $8 billion and medical imaging above $30 billion, suggesting growing expense pressure for diagnosis and treatment.
More related reading
06 · Category
Research & Innovation5 stats
01
The ASCO guidelines update cadence can be quantified by number of guideline documents published per year on ASCO.org for major cancer types
02
NCI’s SEER program covers about 48% of the U.S. population, supporting cancer research and outcomes analyses
03
NCI’s Genomic Data Commons contains data for hundreds of thousands of cancer samples (scale reported in the GDC overview)
04
The Cancer Genome Atlas (TCGA) dataset includes 33 cancer types with molecular characterization across thousands of patients
05
The International Cancer Genome Consortium (ICGC) target includes 50,000 cancer genomes (stated in ICGC program overview materials)
Interpretation
Research & Innovation Interpretation
Together, these Research and Innovation resources show a steep scale-up in genomic and clinical evidence, from TCGA’s 33 cancer types and NCI’s SEER coverage of about 48 percent of the US population to GDC’s hundreds of thousands of samples and ICGC’s 50,000 cancer genomes, enabling faster and more data rich advances across major cancers.
07 · Category
Incidence & Mortality1 stats
01
10.0 million cancer deaths were estimated worldwide in 2020 (all-cause cancer mortality), a measure of deaths attributed to cancer
Interpretation
Incidence & Mortality Interpretation
In the incidence and mortality picture of global cancer, 10.0 million deaths were estimated worldwide in 2020, underscoring cancer’s massive impact on mortality on a year-by-year basis.
08 · Category
Risk Factors3 stats
01
1.6 million cancer deaths per year are attributable to smoking (tobacco smoking attributable cancer mortality)
02
2.5 million cancer deaths per year are attributable to alcohol use globally (alcohol-related cancer mortality)
03
25% of adults globally are physically inactive (insufficient physical activity), contributing to colorectal, breast, and other cancer risks
Interpretation
Risk Factors Interpretation
Risk factors drive a major share of cancer burden, with about 1.6 million deaths per year linked to smoking and 2.5 million to alcohol use, while roughly 25% of adults globally are physically inactive, increasing the likelihood of cancers like colorectal and breast.
09 · Category
Prevention & Screening5 stats
01
39% of the global population is fully vaccinated against HPV (as of 2023 global estimates reported in UNICEF/WHO coverage monitoring)
02
92% of cervical cancer is caused by human papillomavirus (HPV) infection, supporting HPV vaccination and HPV-based prevention
03
70% of colorectal cancers are preventable with screening and removal of precancerous polyps (modeled preventability estimate)
04
20% relative reduction in lung-cancer mortality with low-dose CT screening for high-risk individuals, versus chest X-ray (NLST result)
05
26% relative reduction in lung-cancer mortality with low-dose CT screening in the NELSON trial, versus no screening
Interpretation
Prevention & Screening Interpretation
Prevention and screening efforts could substantially cut cancer burdens, with 39% fully vaccinated against HPV helping address the 92% of cervical cancers linked to HPV and with low-dose CT screening reducing lung cancer mortality by 20% in high-risk groups and by 26% in the NELSON trial.
10 · Category
Industry & Innovation3 stats
01
The global precision oncology (tumor profiling) market is projected to grow at a 10.2% CAGR from 2024 to 2030 (growth rate projection)
02
In 2022, the global number of clinical trials in oncology exceeded 30,000 (study count from clinical trial databases)
03
In 2023, there were 7.9 million patient samples analyzed using next-generation sequencing for cancer diagnostics (sample throughput estimate)
Interpretation
Industry & Innovation Interpretation
With precision oncology tumor profiling set to grow at a 10.2% CAGR from 2024 to 2030 alongside more than 30,000 global oncology clinical trials in 2022 and 7.9 million cancer diagnostic samples analyzed by next-generation sequencing in 2023, the industry is clearly scaling innovation and accelerating translation into real-world testing.
report visual · Breakdown
Global cancer impact: deaths and geographic concentration
Cancer burden is substantial worldwide, with roughly 44% of cancer deaths occurring in Asia alongside about 10.0 million cancer deaths estimated globally in 2020.
90%
WHO’s Global Initiative for Cervical Cancer Elimination targets eliminating cervical cancer as a public health problem b
10%
About 5–10% of all cancers are linked to infections (including HBV/HCV, HPV, H. pylori), per WHO/FAO-hosted cancer infec
source-verifiedwho.int
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). World Cancer Statistics. Gitnux. https://gitnux.org/world-cancer-statistics
MLA
Samuel Norberg. "World Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/world-cancer-statistics.
Chicago
Samuel Norberg. 2026. "World Cancer Statistics." Gitnux. https://gitnux.org/world-cancer-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)